VOR: SEC Form 424B5 filed by Vor Biopharma Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for VOR
Across the 26 sessions after earlier VOR headlines, the stock closed higher 15 times and lower 11 times, with a median move of 3.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | VOR | SPY |
|---|---|---|---|
| Oct 30, 2026 | Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update | -5.9% | -1.8% |
| Oct 23, 2026 | Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy | -3.6% | -0.5% |
| Oct 21, 2026 | William Blair initiated coverage on Vor Biopharma | -0.5% | +0.5% |
| Oct 6, 2026 | Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | -1.5% | +0.5% |
| Sep 29, 2026 | Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis | +0.1% | -0.2% |
| Sep 8, 2026 | Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravisand 1 other headline that session | +0.2% | -0.5% |
Quantisnow market dataNASDAQ
VOR
Vor Biopharma Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2021
Get push alerts for VOR
Full VOR profile on Quantisnow Follow VOR and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time